FDA to 'rapidly work' towards emergency use authorization for Pfizer-BioNTech vaccine
Approval means vaccine distribution would be on Operation Warp Speed's schedule for distribution by mid-month.
The Food and Drug Administration said today that following yesterday's positive advisory committee meeting outcome regarding the Pfizer-BioNTech COVID-19 vaccine, it would rapidly work toward finalization and issuance of an emergency use authorization for the COVID-19 vaccine.
The FDA gave no specific timeline.
The agency has also notified the U.S. Centers for Disease Control and Prevention and Operation Warp Speed so that they can execute their plans for timely vaccine distribution.
Approval means vaccine distribution would be on Operation Warp Speed's schedule for distribution to frontline healthcare workers and vulnerable populations in long-term care facilities by mid-month.
The FDA advisory committee has scheduled another meeting to review the Moderna vaccine on Thursday, December 17.
See our continuing vaccine coverage here:
Pfizer-BioNTech vaccine gets FDA advisory committee approval
CMS offers guidance in billing Medicare for COVID-19 antibody treatment
Thousands in the United Kingdom are the first to receive Pfizer COVID-19 vaccine
Eli Lilly and UnitedHealth Group partner on COVID-19 antibody treatment for high-risk individuals
Operation Warp Speed is looking to start distributing COVID-19 vaccine by mid-month
Moderna seeks regulatory authorization for its COVID-19 vaccine
HHS will begin allocating Regeneron's COVID-19 therapeutic this week
HHS partners with chain and independent pharmacies to increase access to future COVID-19 vaccines
COVID-19 vaccine distribution will begin within 24 hours of an emergency use authorization
Moderna vaccine candidate shows 94.5% efficacy against COVID-19
Pfizer touts new COVID-19 vaccine, calling it '90% effective'
Medicare beneficiaries can get monoclonal antibody COVID-19 treatments at no cost
FDA grants emergency use authorization for Eli Lilly antibody treatment for COVID-19
Twitter: @SusanJMorse
Email the writer: susan.morse@himssmedia.com